Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Institute of Biomedical Research Corp. MRES OTC

Other OTC • Healthcare • Biotechnology • ME • USD

SharesGrow Score
42/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Institute of Biomedical Research Corp. (MRES) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $49,487, +31.4%/yr average growth. Net income is $632,720 (loss), growing at +33.2%/yr. Net profit margin is -1278.6% (negative). Gross margin is 43.2% (+13.7 pp trend).

Balance sheet: total debt is $0 against $583,870 equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.16 (tight liquidity). Debt-to-assets is 0%. Total assets: $3M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 33/100 (Fail), Moat 43/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

MRES SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 43/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MRES

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
MRES: +31.4%/yr revenue is, +33.2%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
MRES: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✗
HEALTH Fail
33/100
Balance sheet MRES: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 0.16 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
43/100
MRES: Gross margin is 43.2% (+13.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
MRES: Net profit margin is -1278.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0007-0.0241
Volume130.84K
Avg Volume (30D)996.44K
Market Cap$5.68M
Beta (1Y)0.04
Share Statistics
EPS (TTM)0.00
Shares Outstanding$2.66B
IPO Date2004-07-29
CEODrasko D. Pekovic
Financial Highlights & Ratios
Revenue (TTM)$49.49K
Gross Profit$21.4K
EBITDA$-724.26K
Net Income$-632.72K
Operating Income$-756.51K
Total Cash$11.8K
Net Debt$-11.8K
Total Assets$3.31M
Price / Earnings (P/E)-10.5
Price / Sales (P/S)114.77
Analyst Forecast
Company Info
CountryME
ExchangeOther OTC
CurrencyUSD
ISINUS45781A1079

Price Chart

Track all markets on TradingView
MRES
Institute of Biomedical Research Corp. ↗  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 0.02

People Also View

SBHMY
SBHMY
Sino Biopharmaceutical Limited
$15.89
+0.00%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 ALRN
ALRN
Aileron Therapeutics, Inc.
$2.11
+9.33%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
 DTCFF
DTCFF
Defence Therapeutics Inc.
$0.44
+9.56%
 ENLV
ENLV
Enlivex Therapeutics Ltd.
$0.80
-4.44%
 LVCLF
LVCLF
Living Cell Technologies Limited
$0.01
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message